Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief ReportArticle Published on 2022-05-012023-07-06 Journal: Clinical lung cancer [Category] COVID19(2023년), [키워드] Cancer care delays NSCLC pandemic SARS-CoV-2 Thoracic oncology. [DOI] 10.1016/j.cllc.2021.08.010 PMC 바로가기
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT RegistryArticle Published on 2022-05-012023-07-08 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), [키워드] Cancer COVID-19 NSCLC registry TERAVOLT Thoracic. [DOI] 10.1016/j.jtho.2021.12.015 PMC 바로가기
Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19증례 보고: 코로나19 증상이 있는 동안 면역 체크포인트 억제를 새로 받은 전이성 비소세포폐암 환자의 임상 관리Case Reports Published on 2021-12-202022-09-12 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] activated ambulatory patient analysis anti-cancer treatment anti-PD1 antiviral immunity blockade CD4 CD8 cellular change clinical Corticosteroid Course COVID-19 CT scan Effect feasible Follow-up healthy High-dose Hospitalized humoral immune response IgG immune checkpoint Immunotherapy inhibition initiated lesion lung cancer male malignancy management metastatic Neutralizing NSCLC Patient PD1 Pembrolizumab Pneumonia Pneumonitis presenting Radiographic SARS-CoV-2 SARS-CoV-2 clearance SARS-COV-2 infection serum sustained symptomatic T cell Tfh the patient treatment initiation worsened [DOI] 10.3389/fimmu.2021.798276 PMC 바로가기 [Article Type] Case Reports
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology폐암 모델, 중증 급성 호흡기 증후군 공개Article Published on 2021-11-012022-09-11 Journal: International Journal of Molecular Sciences [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] ACE2 ACE2 expression acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition AXL bemcentinib bronchial organoids cancer cell lines caused Cell cell surface component coronavirus coronavirus disease Coronavirus disease 2019 Effects EGFR EMT epithelial cells expression growth healthy highlight host cell host cells increasingly induce infected cell infected cells infection with SARS-CoV-2 Infectious disease inhibitor investigated Kinase inhibitor lung cancer Model model system morbidity morbidity and mortality nasal epithelium NSCLC observation occur offer other respiratory virus Other respiratory viruses overexpression Pathogenesis pathogenesis of SARS-CoV-2 Patient Patients with cancer potential mechanism potential mechanisms reduction Regulation repressed respiratory respiratory distress Respiratory distress syndrome respiratory tracts respiratory viruses resulting SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pathogenesis SARS-CoV-2 receptor severe acute respiratory syndrome Coronavirus surface protein the cell tight junction tissue tissues TMPRSS2 transcriptional transcriptional change transforming growth factor transition tyrosine tyrosine kinase inhibitor up-regulation variety viruses ZEB1 ZEB1. [DOI] 10.1016/j.jtho.2021.07.002 PMC 바로가기 [Article Type] Article
Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint BlockadeReview Published on 2021-06-112023-08-30 Journal: Cancers [Category] E형 간염, [키워드] Immune checkpoint blockade LUAD LUSC NSCLC Tumor immune microenvironment [DOI] 10.3390/cancers13122924 PMC 바로가기 [Article Type] Review
The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung CancerOriginal Research Published on 2021-02-172023-08-30 Journal: Frontiers in Oncology [Category] E형 간염, [키워드] anlotinib hydrochloride EGFR NSCLC third line of therapy TP53 [DOI] 10.3389/fonc.2020.619010 PMC 바로가기 [Article Type] Original Research
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) – novel approaches and future outlookReview Published on 2020-09-112023-08-30 Journal: Molecular Cancer [Category] E형 간염, [키워드] Immunotherapy resistance NSCLC targeted therapy Tumor microenvironment heterogeneity [DOI] 10.1186/s12943-020-01260-z PMC 바로가기 [Article Type] Review
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 PandemicOncology Published on 2020-05-122022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] acute respiratory syndrome added approaches Cell coronavirus COVID-19 COVID19 determine Duration Efficacy exploratory analysis Factor first line fixed Immune checkpoint inhibitors inhibitor lung cancer management NSCLC pandemic Patient physician Pragmatic Prognosis progression Prospective trial question Rethinking Standard therapy survival rate therapeutic Toxicity Treatment Trial trials were used [DOI] 10.3389/fonc.2020.00862 PMC 바로가기 [Article Type] Oncology
Newly developed anti-angiogenic therapy in non-small cell lung cancerReview Published on 2018-02-092023-08-29 Journal: Oncotarget [Category] E형 간염, [키워드] Angiogenesis combined with chemotherapy Immunotherapy NSCLC tyrosine kinase inhibitor [DOI] 10.18632/oncotarget.23755 PMC 바로가기 [Article Type] Review